Need a supporting hand in manuscript formatting? Write to our team.
Assistance in presubmission | editorialoffice@clinmedjournals.org


Research Article  |   Volume 3, Issue 6

Cancer Antigen 125 Levels can be Used as a Tumor Marker for Monitoring Patients with Endometrial Serous Carcinoma?

MW Hegazy, Wael H Elsawy, A Tolba and M Shoukri

Endometrial adenocarcinoma is the most common type of uterine cancer. Endometrial cancer is classified into two subtypes (I and II), which reflect general characteristics of its clinicopathological spectrum. Uterine serous adenocarcinoma (USAC) is under Type II neoplasms which are associated with more aggressive behavior than type I tumors. While they comprise 10-20% of endometrial carcinomas, they account for 40% of deaths from the disease.

  PDF   |    Full Text | DOI: 10.23937/2378-3419/3/6/1075

Clinical Image  |   Volume 3, Issue 6

Massive Arterial Bleeding after Lenvatinib Therapy for Thyroid Cancer

Koichi Suyama, DaizoMurakami, Saori Fujiwara, Takashi Takeshita, Aiko Sueta, ToukoInao, Mutsuko Yamamoto-Ibusuki, Yutaka Yamamoto, Shin-yaShiraishi and Hirotaka Iwase

A 69-year-old woman presented with hoarseness and other symptoms of laryngeal stenosis. A palpably large tumorin her neck was shown by computed tomography (CT) to expand invasively from her upper left thyroid lobe, and to involve her left common carotid artery and internal jugular vein (Figure 1 A-1). The diagnosis of papillary thyroid cancer was based on cytological evidence from fine needle aspiration biopsy.

  PDF   |    Full Text | DOI: 10.23937/2378-3419/3/6/1074

Short Review  |   Volume 3, Issue 6

Pigmented Paget Disease of the Nipple: A Rare Breast Cancer Presentation

Santiago Sherwell-Cabello, Antonio Maffuz-Aziz, Silvia Natalia Lopez-Hernandez, Melissa Lizeth Flores-Cortes, Veronica Bautista-Pina and Sergio Rodriguez-Cuevas

Institutional board approval was obtained before commencement of this study. A retrospective study was conducted in all women diagnosed with breast cancer at our institution from January 2005 to December 2013. Standard immunohistochemical breast cancer panel was performed to all patients (ER, PR, Her-2 and Ki-67) and CK-7, P63 and S-100 when the pigmented variety was presented. Patients with pigmented Paget disease were selected and demographic characteristics were established.

  PDF   |    Full Text | DOI: 10.23937/2378-3419/3/6/1073

Review Article  |   Volume 3, Issue 6

Colorectal Cancer Aggressiveness is Related to Fibronectin Over Expression, Driving the Activation of SDF-1:CXCR4 Axis

Sofia Gouveia-Fernandes, Tania Carvalho, Germana Domingues, Renata Bordeira-Carrico, Sergio Dias and Jacinta Serpa

Cancer hallmarks result from dynamical interactions between tumor cells and tumor microenvironment, including normal cells, growth factors and extracellular matrix (ECM) components. Fibronectin (FN) is a high molecular weight, multidomain glycoprotein, present as a soluble form in body fluids, such as plasma (plasma FN), and as an insoluble form in ECM (cellular FN).

  PDF   |    Full Text | DOI: 10.23937/2378-3419/3/6/1072

Case Report  |   Volume 3, Issue 6

Prolonged Use of Aprepitant in Metastatic Breast Cancer and a Reduction in CA153 Tumour Marker Levels

Mark Lee, Matthew McCloskey and Stephanie Staples

Nausea and vomiting are common problems in patients with advanced cancer. This case report describes a patient whose refractory nausea and vomiting improved significantly with the use of Aprepitant, a highly selective neurokinin 1 receptor antagonist. This improvement led to prolonged daily administration, during which time no chemotherapy or hormone therapy was administered. CA153 tumour markers were noted to have fallen during administration.

  PDF   |    Full Text | DOI: 10.23937/2378-3419/3/6/1071